Inipharm commences dosing in INI-822 trial for MASH

Inipharm has started dosing in a 12-week proof-of-concept clinical study evaluating its oral HSD17B13 inhibitor, INI-822, in adults with MASH. Genetic studies show variants cutting HSD17B13 enzyme activity reduce risk of progressive fibrotic liver diseases, including fibrotic MASH. Credit: Gorodenkoff / Shutterstock.com. Inipharm has started dosing in a 12-week proof-of-concept clinical study evaluating its oral hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) inhibitor, INI-822, in adults with metabolic dysfunction-associated steatohepatitis (MASH). The placebo-controlled, double-blind trial aims to enrol approximately 50 MASH patients. It will measure safety, pharmacokinetics, and tolerability and evaluate changes in MASH-related biomarkers and fibrosis, using FibroScan technology. LOA and PTSR…

Source: Clinical Trials Arena